Logo
Login

Company Executives

$ Management Team

Mr. Thomas Civik

Independent Chairman of the Board

Age 53
Compensation $946.6K USD
Sex Male

Mr. Lloyd Segal

President

Chief Executive Officer

Director

Age 58
Compensation $3.910M USD
Sex Male

Mr. Steve Forte

Chief Financial Officer

Executive Vice President

Age 43
Compensation $2.310M USD
Sex Male

Dr. Michael Zinda

Executive Vice President

Chief Scientific Officer

Age 51
Compensation $3.652M USD
Sex Male

Dr. Maria Koehler

Executive Vice President

Chief Medical Officer

Age 66
Compensation $3.666M USD
Sex Female

Ms. Kimberly Minarovich

Investor Relations

Age -
Compensation -
Sex Female

Board of Directors

From the proxy statement filed Apr 29, 2025
Directors
8
serving now
Independent
7 of 8
stated in the proxy
Average tenure
3.8 years
from year joined
CEO also chairs the board
No
Thomas Civik
Director Age On board Independent Committees Other public boards 2024 pay Source
David Bonita, M.D.
49 2019
6 years
 Independent
Compensation Science and Technology
Acutus Medical Inc., Ikena Oncology, Inc., Prelude Therapeutics Inc., Third Harmonic Bio, Inc. $119,060
Thomas Civik
Board chair
 56 2021
4 years
 Independent None stated Pyxis Oncology, Inc. $149,201
Carol A. Schafer
61 2019
6 years
 Independent
Nominating and Corporate Governance · Chair
Immunome, Inc., Insmed, Inc, Kura Oncology, Inc. $128,806
Steven Stein, M.D.
58 2024
1 year
 Independent None stated None stated $172,311
Steve Forte
CEO
 46 2025
0 years
 Not independent None stated None stated Paid as CEO
Samarth Kulkarni, Ph.D.
46 2019
6 years
 Independent None stated Black Diamond Therapeutics, Inc., Oruka Therapeutics, Centessa Pharmaceuticals plc $118,430
Susan M. Molineaux, Ph.D.
71 2023
2 years
 Independent None stated Geron Corporation $122,847
Ann D. Rhoads
59 2020
5 years
 Independent
Audit · Chair
Globus Medical Inc., QuidelOrtho Corporation (formerly Quidel Corporation), iTeos Therapeutics Inc. $130,138

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 29, 2025 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans